亞太藥業(002370.SZ):控股股東擬增持不低於2000萬元公司股份 已增持446.54萬股
格隆匯2月6日丨亞太藥業(002370.SZ)公佈,公司於2024年2月6日收到公司控股股東寧波富邦控股集團有限公司(簡稱“富邦集團”)的通知,富邦集團於2024年2月6日以自有資金通過深圳證券交易所繫統以集中競價交易方式增持公司股份446.54萬股,增持金額1330.1099萬元,佔公司總股本的0.73%。
基於對公司未來持續穩定發展的信心和對公司長期價值的認可,為維護資本市場穩定,提振投資者信心,維護中小股東利益,同時進一步鞏固控股股東地位,促進公司持續、穩定、健康的發展,富邦集團擬自2024年2月6日起6個月內,通過深圳證券交易所交易系統以集中競價交易方式繼續增持公司股份,增持金額不低於人民幣2,000萬元(含2024年2月6日增持金額)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.